Agilent Technologies Inc (A): Mark Doak , Sr. Vice President of Agilent Technologies Inc sold 18,879 shares on May 19, 2016. The Insider selling transaction was reported by the company on May 20, 2016 to the Securities and Exchange Commission. The shares were sold at $44.14 per share for a total value of $833,319.06 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 19, 2016, Rodney Gonsalves (V.P., Corporate Controller) sold 9,542 shares at $44.24 per share price.On May 12, 2016, Dominique Grau (Senior Vice President) sold 10,322 shares at $43.00 per share price.Also, On Apr 4, 2016, Heidi Fields (director) sold 30,000 shares at $39.91 per share price.On Mar 21, 2016, Robert J Herbold (director) sold 8,072 shares at $40.30 per share price.
Agilent Technologies Inc: On Thursday, May 19, 2016 heightened volatility was witnessed in Agilent Technologies Inc which led to swings in the share price. The shares opened for trading at $44.07 and hit $44.82 on the upside , eventually ending the session at $44.56, with a gain of 0.54% or 0.24 points. The heightened volatility saw the trading volume jump to 36,60,160 shares. The 52-week high of the share price is $45.34 and the company has a market cap of $14,605 M . The 52-week low of the share price is at $33.115.
Company has been under the radar of several Street Analysts.Agilent Technologies Inc is Reiterated by Jefferies to Buy and the brokerage firm has raised the Price Target to $ 51 from a previous price target of $46 .The Rating was issued on May 17, 2016.Agilent Technologies Inc is Reiterated by Barclays to Equal Weight and the brokerage firm has raised the Price Target to $ 45 from a previous price target of $42 .The Rating was issued on May 17, 2016.
Agilent Technologies Inc. is engaged in the life sciences diagnostics and applied chemical markets. The Company provides application focused solutions that include instruments software services and consumables for the entire laboratory workflow. The Company has three business segments: the life sciences and applied markets business the diagnostics and genomics business and the Agilent CrossLab business. The Company’s life sciences and applied markets business segment brings together the Company’s analytical laboratory instrumentation and informatics. The Company’s diagnostics and genomics business segment consists of three businesses: the Dako business the genomics business and the nucleic acid solutions business. The Company’s Agilent CrossLab business segment combines its analytical laboratory services and consumables business.